Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Clay Thorp sold 5,000 shares of Clearside Biomedical stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $6.13, for a total value of $30,650.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Clay Thorp also recently made the following trade(s):

  • On Tuesday, December 5th, Clay Thorp sold 15,000 shares of Clearside Biomedical stock. The shares were sold at an average price of $6.37, for a total value of $95,550.00.
  • On Tuesday, November 14th, Clay Thorp sold 15,000 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.02, for a total value of $105,300.00.
  • On Thursday, November 16th, Clay Thorp sold 35,000 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.00, for a total value of $245,000.00.
  • On Thursday, October 5th, Clay Thorp sold 35,000 shares of Clearside Biomedical stock. The shares were sold at an average price of $8.57, for a total value of $299,950.00.
  • On Thursday, September 14th, Clay Thorp sold 6,000 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.52, for a total value of $45,120.00.
  • On Wednesday, September 13th, Clay Thorp sold 8,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.49, for a total value of $63,665.00.
  • On Friday, September 15th, Clay Thorp sold 24,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.52, for a total value of $184,240.00.

Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) traded up $0.23 during trading hours on Thursday, hitting $6.20. The stock had a trading volume of 204,744 shares, compared to its average volume of 152,443. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.57 and a quick ratio of 4.57. Clearside Biomedical, Inc. has a 1-year low of $5.44 and a 1-year high of $14.14.

Clearside Biomedical (NASDAQ:CLSD) last issued its earnings results on Wednesday, November 8th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.17). Clearside Biomedical had a negative return on equity of 90.72% and a negative net margin of 17,684.07%. The firm had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.01 million. sell-side analysts forecast that Clearside Biomedical, Inc. will post -2.33 EPS for the current year.

A number of brokerages have recently issued reports on CLSD. ValuEngine cut Clearside Biomedical from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Zacks Investment Research cut Clearside Biomedical from a “hold” rating to a “sell” rating in a report on Friday, August 11th. TheStreet cut Clearside Biomedical from a “c-” rating to a “d” rating in a report on Friday, August 11th. Finally, Cowen reiterated a “buy” rating on shares of Clearside Biomedical in a report on Wednesday, October 25th. Two analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. Clearside Biomedical currently has an average rating of “Hold” and an average target price of $18.33.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nationwide Fund Advisors boosted its holdings in Clearside Biomedical by 118.3% in the 2nd quarter. Nationwide Fund Advisors now owns 11,703 shares of the company’s stock worth $107,000 after acquiring an additional 6,343 shares during the period. Citadel Advisors LLC purchased a new position in Clearside Biomedical in the 2nd quarter worth approximately $117,000. Parametric Portfolio Associates LLC purchased a new position in Clearside Biomedical in the 2nd quarter worth approximately $122,000. ProShare Advisors LLC boosted its holdings in Clearside Biomedical by 4.0% in the 2nd quarter. ProShare Advisors LLC now owns 14,814 shares of the company’s stock worth $135,000 after acquiring an additional 563 shares during the period. Finally, State of Wisconsin Investment Board purchased a new position in Clearside Biomedical in the 2nd quarter worth approximately $137,000. Hedge funds and other institutional investors own 51.73% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Clearside Biomedical, Inc. (CLSD) Director Sells 5,000 Shares of Stock” was published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/07/insider-selling-clearside-biomedical-inc-clsd-director-sells-5000-shares-of-stock.html.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

Insider Buying and Selling by Quarter for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.